Your browser doesn't support javascript.
loading
BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm, Michael; Sohier, Pierre; Petit, Valérie; Raymond, Jérémy H; Delmas, Véronique; Le Coz, Madeleine; Gesbert, Franck; Kenny, Colin; Aktary, Zackie; Pouteaux, Marie; Rambow, Florian; Sarasin, Alain; Charoenchon, Nisamanee; Bellacosa, Alfonso; Sanchez-Del-Campo, Luis; Mosteo, Laura; Lauss, Martin; Meijer, Dies; Steingrimsson, Eirikur; Jönsson, Göran B; Cornell, Robert A; Davidson, Irwin; Goding, Colin R; Larue, Lionel.
Afiliación
  • Hamm M; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Sohier P; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Petit V; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Raymond JH; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Delmas V; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Le Coz M; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Gesbert F; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Kenny C; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Aktary Z; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Pouteaux M; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Rambow F; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Sarasin A; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Charoenchon N; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Bellacosa A; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Sanchez-Del-Campo L; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Mosteo L; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Lauss M; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Meijer D; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Steingrimsson E; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Jönsson GB; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
  • Cornell RA; Equipes Labellisées Ligue Contre le Cancer, Paris, France.
  • Davidson I; Department of Anatomy and Cell biology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
  • Goding CR; Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Normal and Pathological Development of Melanocytes, Orsay, France.
  • Larue L; Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation radiobiologie et cancer, Orsay, France.
Nat Commun ; 12(1): 3707, 2021 06 17.
Article en En | MEDLINE | ID: mdl-34140478
While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A, have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a BrafV600E PtenF/+ context, we show that BRN2 haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces PTEN expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses PTEN transcription. Collectively, our results suggest that on a PTEN heterozygous background somatic deletion of one BRN2 allele and temporal regulation of the other allele elicits melanoma initiation and progression.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Regulación Neoplásica de la Expresión Génica / Genes Supresores de Tumor / Proteínas de Homeodominio / Proliferación Celular / Factores del Dominio POU / Carcinogénesis / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Regulación Neoplásica de la Expresión Génica / Genes Supresores de Tumor / Proteínas de Homeodominio / Proliferación Celular / Factores del Dominio POU / Carcinogénesis / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Francia